11/25
07:19 am
nbtx
Nanobiotix (NASDAQ:NBTX) had its "outperform" rating reaffirmed by analysts at Leerink Partners.
Low
Report
Nanobiotix (NASDAQ:NBTX) had its "outperform" rating reaffirmed by analysts at Leerink Partners.
11/24
04:15 pm
nbtx
Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical Outlook
Medium
Report
Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical Outlook
11/14
02:00 am
nbtx
Voting Rights and Shares Capital of the Company
Medium
Report
Voting Rights and Shares Capital of the Company
11/11
04:37 pm
nbtx
NANOBIOTIX to Participate in Jefferies London Healthcare Conference [Yahoo! Finance]
Medium
Report
NANOBIOTIX to Participate in Jefferies London Healthcare Conference [Yahoo! Finance]
11/11
04:15 pm
nbtx
NANOBIOTIX to Participate in Jefferies London Healthcare Conference
Medium
Report
NANOBIOTIX to Participate in Jefferies London Healthcare Conference
11/4
08:44 am
nbtx
Nanobiotix (NASDAQ:NBTX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Nanobiotix (NASDAQ:NBTX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
11/3
04:15 pm
nbtx
NANOBIOTIX to Participate in Investor Conferences the Week of November 10th
Medium
Report
NANOBIOTIX to Participate in Investor Conferences the Week of November 10th
10/31
03:00 am
nbtx
NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth
High
Report
NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth
10/25
01:32 am
nbtx
High
Report
10/24
02:07 am
nbtx
NANOBIOTIX Announces Updates to JNJ-1900 (NBTXR3) Clinical Program Following Transfer of Ongoing Phase 3 Head and Neck Cancer Trial Sponsorship and Operational Control [Yahoo! Finance]
Low
Report
NANOBIOTIX Announces Updates to JNJ-1900 (NBTXR3) Clinical Program Following Transfer of Ongoing Phase 3 Head and Neck Cancer Trial Sponsorship and Operational Control [Yahoo! Finance]
10/24
02:00 am
nbtx
NANOBIOTIX Announces Updates to JNJ-1900 (NBTXR3) Clinical Program Following Transfer of Ongoing Phase 3 Head and Neck Cancer Trial Sponsorship and Operational Control
Low
Report
NANOBIOTIX Announces Updates to JNJ-1900 (NBTXR3) Clinical Program Following Transfer of Ongoing Phase 3 Head and Neck Cancer Trial Sponsorship and Operational Control
10/15
02:00 am
nbtx
Voting Rights and Shares Capital of the Company
Medium
Report
Voting Rights and Shares Capital of the Company
10/10
06:11 pm
nbtx
This Stock Is Up 440% in a Year. Is It an Undiscovered Star or a Flash in the Pan? [Yahoo! Finance]
High
Report
This Stock Is Up 440% in a Year. Is It an Undiscovered Star or a Flash in the Pan? [Yahoo! Finance]
10/8
12:30 pm
nbtx
Nanobiotix (NASDAQ:NBTX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Nanobiotix (NASDAQ:NBTX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/7
08:00 am
nbtx
Novel Cancer Platforms Converge as Clinical Data Reshapes Treatment Paradigms
Low
Report
Novel Cancer Platforms Converge as Clinical Data Reshapes Treatment Paradigms
10/7
08:00 am
nbtx
Novel Cancer Platforms Converge as Clinical Data Reshapes Treatment Paradigms
Low
Report
Novel Cancer Platforms Converge as Clinical Data Reshapes Treatment Paradigms
10/3
07:44 am
nbtx
Nanobiotix's HNSCC hopeful wins in Phase I oesophageal cancer trial [Yahoo! Finance]
Low
Report
Nanobiotix's HNSCC hopeful wins in Phase I oesophageal cancer trial [Yahoo! Finance]
10/1
04:23 pm
nbtx
NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer [Yahoo! Finance]
Medium
Report
NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer [Yahoo! Finance]
10/1
04:15 pm
nbtx
NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer
Medium
Report
NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer
10/1
10:14 am
nbtx
Nanobiotix S.A. GAAP EPS of -€0.11, revenue of €26.6M [Seeking Alpha]
Low
Report
Nanobiotix S.A. GAAP EPS of -€0.11, revenue of €26.6M [Seeking Alpha]
9/30
10:15 pm
nbtx
NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results [Yahoo! Finance]
Low
Report
NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results [Yahoo! Finance]
9/30
04:15 pm
nbtx
NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results
Medium
Report
NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results
9/30
01:59 pm
nbtx
Nanobiotix-J&J Therapy Shows Promise In Tough Head And Neck Cancer [Yahoo! Finance]
Low
Report
Nanobiotix-J&J Therapy Shows Promise In Tough Head And Neck Cancer [Yahoo! Finance]
9/29
07:17 pm
nbtx
NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC [Yahoo! Finance]
Medium
Report
NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC [Yahoo! Finance]
9/29
06:30 pm
nbtx
NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC
Medium
Report
NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC